Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(16)31740-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.
Lancet Reg Health Eur
February 2025
Karolinska Institutet, Oncology/Pathology Department, Stockholm, Sweden.
Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit.
Methods: The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel (D) administered in either tailored dose-dense (tDD EC/D) or standard interval schedule (FEC/D) to patients with high-risk resected early breast cancer (n = 2003). We compared outcomes across key subgroups of interest, evaluated the performance of the online prognostication and treatment benefit estimation tool PREDICT and conducted a subpopulation treatment effect pattern plot (STEPP) analysis.
Background: Distant recurrence in women with oestrogen receptor-positive early breast cancer persists at a constant rate for more than 20 years after diagnosis, with little equivalent data for oestrogen receptor-negative breast cancer. Using the database of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) we investigated rates of distant breast-cancer recurrence in oestrogen receptor-positive and oestrogen receptor-negative tumours and trends in outcomes over time.
Methods: In this pooled analysis of randomised controlled trial data, patients in the EBCTCG database of more than 650 000 women in trials of treatment for early-stage breast cancer were screened for eligibility.
Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue.
Sci Rep
August 2024
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Formalin-fixed paraffin-embedded (FFPE) tissue represents a valuable source for translational cancer research. However, the widespread application of various downstream methods remains challenging. Here, we aimed to assess the feasibility of a genomic and gene expression analysis workflow using FFPE breast cancer (BC) tissue.
View Article and Find Full Text PDFNeoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.
J Natl Cancer Inst
October 2024
Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Article Synopsis
- - The KEYNOTE-522 trial studied the effects of neoadjuvant pembrolizumab combined with chemotherapy on patients with early-stage triple-negative breast cancer, showing improved pathological complete response and event-free survival compared to chemotherapy alone.
- - Patients were randomly assigned to receive either pembrolizumab or placebo alongside chemotherapy, followed by additional pembrolizumab post-surgery; quality of life was measured using specific questionnaires during the treatment phases.
- - Results indicated no significant differences in overall quality of life and emotional/physical functioning between the treatment and placebo groups during the neoadjuvant and adjuvant phases, although some aspects of physical functioning showed minor statistical differences.
Application frequency - key indicator for the efficiency of severe dry eye disease treatment - evidence for the importance of molecular weight of hyaluronan in lubricating agents.
Acta Ophthalmol
August 2024
Department of Ophthalmology, Medical University of Graz, Graz, Austria.
Article Synopsis
- The study investigates the effectiveness of high molecular weight hyaluronan (HA) eye drops in reducing the frequency of eye drop applications in patients with severe dry eye disease (DED).
- It compares patients using these high Mw HA drops (hylan A) with those using lower Mw HA drops over an 8-week period, measuring changes in drop frequency and overall eye health.
- Results showed that hylan A users significantly decreased their eye drop frequency by week 4 and maintained this improvement up to week 8, with noticeable benefits in their ocular health metrics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!